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Abstract
 
Interleukin (IL)-12 is a heterodimeric cytokine consisting of the p40 and p35 chains encoded
on separate chromosomes. Coordinated expression of the two constituent genes is crucial for
appropriate immune responses in timing, location, and magnitude. Interferon (IFN)-
 
  
 
priming
of IL-12 production by macrophages represents an important physiological process in vivo for
escalated cellular response to microbial infections. We provide evidence that IFN regulatory
factor (IRF)-1–deficient macrophages have a selective impairment in mRNA synthesis of IL-12
p35 but not the p40 gene, and a strong deficiency in the production of IL-12 p70 but not p40.
We demonstrate that the levels of IL-12 p35 protein stimulated by IFN-
 
  
 
and lipopolysaccharide
(LPS) correspond to those of its mRNA, and that the nuclear factor 
 
 
 
B signaling pathway is
essential for the induction of IL-12 p35 transcription by LPS. IRF-1 plays a major role in the
transcriptional activation of the IL-12 p35 gene, but not of the p40 gene, by physically inter-
acting with an inverted IRF element within the IL-12 p35 promoter upon IFN-
 
  
 
activation.
Moreover, IRF-1–mediated transcriptional activation of the p35 promoter requires the coop-
eration of two adjacent Sp1 elements. Thus, IRF-1 acts as a critical component of IFN-
 
  
 
signaling
in the selective activation of IL-12 p35 transcription in synergy with LPS-mediated events.
Key words: IL-12 • IFN-
 
  
 
•
 
 
 
IRF-1 • macrophage • transcription
 
Introduction
 
IL-12 is produced primarily by macrophages and DCs in
both innate and adaptive immune responses. It is a key factor
in the induction of T cell–dependent and –independent
activation of macrophages, NK cells, generation of Th1
cells, and CTLs, induction of opsonic, complement-fixing
antibodies, and resistance to intracellular infections (1).
Pathogens and tumor cells, on the other hand, often evade
immune activation by producing immunosuppressive agents
such as IL-10, TGF-
 
 
 
, and prostaglandin E2 that can in-
hibit IL-12 production, among other things, resulting in
much weakened immune recognition and /or activation (2).
The control of IL-12 production by APCs is complicated
by the fact that IL-12 is composed of two heterologous
chains, p40 and p35. The genes encoding IL-12 p40 and
p35 are located on different human and mouse chromo-
somes (3). The highly coordinated expression of p40 and
p35 genes to form IL-12 (also called p70) in the same cell
type at the same time is essential for the initiation of an
effective immune response. The molecular mechanisms by
which IL-12 p40 gene expression is regulated in APCs
have been studied extensively in the last 7 yr and some
important mediators and effectors have been identified (4–8).
In contrast, the regulation of the p35 gene expression has
not been given sufficient attention for a number of practical
reasons. First, there was a misimpression that the p35 gene
was “constitutively” and “ubiquitously” expressed and
therefore not as interesting to study as the more inducible
p40 gene. Second, the induction of p35 in APCs requires
two signals typically provided by LPS and IFN-
 
 
 
, respec-
tively, making it more challenging to sort out the intermingled
processes (5, 9). Third, there has been a lack of useful reagents
with which to probe the pathway that leads to the induction
of the p35 gene. Several recent studies, however, have shed
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Abbreviations used in this paper:
 
 ChIP, chromatin immunoprecipitation;
IRF, IFN regulatory factor; MOI, multiplicity of infection; NF, nuclear
factor; RPA, RNase protection assay.T
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new light on the transcriptional regulation of this gene and
stirred reinvigorated enthusiasm for further exploration of
the control of IL-12 p35 gene expression in immune re-
sponses. Among these studies that used gene knockout mice
and overexpression approaches, IFN regulatory factor
(IRF)-1 and nuclear factor (NF)-
 
 
 
B c-Rel are strongly im-
plicated to be important transcription factors for IFN-
 
 
 
–
primed and LPS-induced p35 transcription, respectively
(10–13). However, the molecular details of how IRF-1 reg-
ulates the p35 gene transcription remain to be elucidated.
IRF-1 is the first member of the IRF family of nine cel-
lular genes identified as a transcription factor induced dur-
ing a viral infection that bound to the IFN-
 
  
 
promoter (14,
15). Intensive analyses focused on IRF-1 because its initial
discovery has revealed a remarkable functional diversity of
this molecule in the regulation of cellular response in host
defense. IRF-1 selectively targets different sets of genes in
various cell types in response to diverse cellular stimuli and
evokes appropriate innate and adaptive immune responses
(16). IRF-1 has been firmly established as a critical effector
molecule in IFN-
 
 
 
–mediated signaling and in the develop-
ment and function of NK and NKT cells, and CTLs (10,
17–21). The first demonstration of the importance of IRF-1
in IL-12 production and IL-12–mediated induction of Th1
immune responses was provided by the work of Taki et al.
(10) who showed that T cells from mice lacking IRF-1
failed to mount Th1 responses and instead exclusively un-
derwent Th2 differentiation in vitro. Compromised Th1
differentiation was associated with defects in IL-12 produc-
tion by macrophages and hyporesponsiveness of CD4
 
  
 
T
cells to IL-12. This study provides a mechanistic explana-
tion for the IFN-
 
 
 
–priming effect, i.e., IFN-
 
 
 
–mediated
activation of APCs that is required for vigorous IL-12 pro-
duction to generate robust cellular immunity.
In this study, we mainly address the following question:
how does IRF-1 regulate IL-12 p40 and p35 gene expression?
 
Materials and Methods
 
Mice.
 
IRF-1
 
 
 
/
 
  
 
mice and their control, C57BL/6J mice, were
obtained from The Jackson Laboratory. All mice were female and
 
 
 
6–8 wk old. Mice were housed in cages with filter tops in a lam-
inar flow hood and fed food and acid water ad libitum.
 
Cells.
 
The murine macrophage cell line RAW 264.7 (RAW
cells hereafter) was obtained from American Type Culture Collec-
tion and maintained in RPMI 1640 supplemented with 2 mM glu-
tamine, 100 units/ml of penicillin and streptomycin, and 10% FBS
(endotoxin 
 
 
 
1 ng/ml; Hyclone). Resident peritoneal macrophages
were obtained directly from the peritoneum cavity, and inflamma-
tory peritoneal exudate macrophages were obtained by lavage 4 d
after injection of sterile 3% thioglycollate broth (1 ml i.p.). Cells
were washed and resuspended in RPMI containing 10% FCS and
standard supplements. Macrophages were plated in 24-well tissue
culture dishes (0.5 
 
  
 
10
 
6 
 
cells/well). After 2 h of incubation to al-
low for adherence of macrophages, monolayers were washed three
times to remove nonadherent cells and incubated with RPMI con-
taining 10% FCS and standard supplements. The next day some
wells were treated with 1 
 
 
 
g/ml LPS in a final volume of 1 ml, or
10 ng/ml IFN-
 
  
 
first for 16 h (priming) followed by LPS.
Human monocytes were isolated from fresh blood by Ficoll/
Hypaque gradient centrifugation. Mononuclear cells were incu-
bated for 1 h in polystyrene tissue culture flasks (Falcon; Becton
Dickinson). To generate macrophages, adherent cells, typically
 
 
 
85% CD14
 
  
 
by FACS
 
® 
 
analysis, were cultured in complete me-
dia supplemented with 100 ng/ml human M-CSF (PeproTech)
for 6 d. The resulting cells were 
 
 
 
95% F408
 
  
 
macrophages.
 
Reagents.
 
All antibodies used in this study were purchased
from Santa Cruz Biotechnology, Inc. The anti–human IL-12 p35
rabbit IgG from Santa Cruz Biotechnology, Inc. that was used in
IL-12 p35 Western blot is H-197. Expression vectors pAct-1
(IRF-1), pAct-2 (IRF-2), and control pAct-C were provided by
T. Taniguchi (University of Tokyo, Tokyo, Japan). The “domi-
nant positive mutant” of I
 
 
 
B
 
  
 
was originally generated in the
laboratory of H.C. Liou at Weill Medical College of Cornell
University. It was made by deleting the first 38 amino acids of
I
 
 
 
B
 
  
 
that contained the two critical serine residues in the phos-
phorylation sites, making this mutant resistant to intracellular
degradation mediated through phosphorylation. According to
H.C. Liou (personal communication), this truncated I
 
 
 
B
 
  
 
has a
potent inhibitory effect on NF-
 
 
 
B activity in B cells. The expres-
sion vectors for NF-
 
 
 
B p50, p65, and c-Rel were provided by K.
Murphy (University of Washington, St. Louis, MO) and have
been described (4). All plasmid DNA were prepared with
QIAGEN Endo-free Maxi-Prep kits (QIAGEN). Murine TNF-
 
 
 
was purchased from Genzyme. Recombinant human and mouse
IL-12 were provided by the Genetics Institute.
 
ELISAs.
 
Supernatants from macrophage cultures were har-
vested at 6, 12, and 24 h after LPS stimulation and stored at
 
 
 
70
 
 
 
C. Mouse and human IL-12 p70 and p40 were detected by
using the OPT-EIA ELISA kit (BD Biosciences) according to the
manufacturer’s instructions. Concentrations were calculated by
regression analysis of a standard curve. Data are expressed as pico-
grams per milliliter.
 
RNase Protection Assay (RPA).
 
Mouse macrophages and hu-
man peripheral blood monocytes were pretreated with IFN-
 
 
 
for 16 h followed by treatment with LPS for an additional 4 h.
10 
 
 
 
g total RNA for each determination was subjected to multi-
probe RNase protection kit (BD Biosciences), mCK2b for
mouse and hCK2 for human samples, according to the manufac-
turer’s instructions.
 
Nuclear Extract Preparation.
 
Nuclear extracts for Western blot
and DNA affinity binding assays were prepared according to the
methods of Schreiber et al. (22).
 
Western Blotting.
 
SDS-PAGE was performed according to
Laemmli (23). Gels were electroblotted to nitrocellulose mem-
branes and blocked in 5% milk in Tris buffer, pH 8.0. Primary
antibody was added at the concentration of 1 
 
 
 
g/ml in Tris
buffer containing 1% milk powder and left overnight at 4
 
 
 
C. Af-
ter extensive washing, secondary antibody conjugated to horse-
radish peroxidase was added at a 1:5,000 dilution in 5% milk.
After extensive washing, blots were subjected to enhanced chemi-
luminescence detection (PerkinElmer).
 
Transfection Assay.
 
Transient transfections were performed by
electroporation as previously described (5).
 
DNA Affinity Binding Assay.
 
Complementary biotinylated
oligonucleotides encompassing the human IL-12 p35 promoter
IRF-E site (
 
 
 
229/
 
 
 
249) or the mutant IRF-E were synthesized
and annealed. 2 
 
 
 
g biotinylated dsDNA were conjugated to 100
 
 
 
l streptavidin-bound magnetic beads (Dynabeads, M280; Dynal)
in binding/washing buffer (10 mM Tris-HCl, pH 8.0, 1 mM
EDTA, 0.1 M NaCl) for 30 min at room temperature. Unconju-
gated DNA was collected with a magnetic particle concentrator.T
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DNA-conjugated beads were then blocked by 0.5% BSA in
TGEDN buffer (120 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 M
NaCl, 1 mM DTT, 0.1% Triton X-100, and 10% glycerol) at
room temperature for 1 h. Beads were washed once in TGEDN
buffer and resuspended in 50 
 
 
 
l TGEDN. 10 
 
 
 
l beads conjugated
to 2 
 
 
 
g DNA were equilibrated with TGEDN buffer and incu-
bated with 500 
 
 
 
g RAW cell nuclear extracts and 20 
 
 
 
g herring
sperm DNA (Sigma-Aldrich) at 4
 
 
 
C for 2 h. Beads were washed
in TGEDN buffer and bound materials were eluted in 20 
 
 
 
l the
same buffer supplemented with 0.5% SDS and 1 M NaCl. Eluted
materials and unconjugated protein were separated by 12% SDS-
PAGE and detected by immunoblot analysis using rabbit anti–
IRF-1 or anti–PU.1 antibody with the enhanced chemilumines-
cence kit (PerkinElmer). Nuclear extracts were prepared from
RAW cells treated with 10 ng/ml IFN-
 
  
 
for 16h followed by in-
cubation with LPS plus IFN-
 
  
 
for an additional 4 h.
 
RT-PCR.
 
RT reactions were performed as follows: 2 
 
 
 
g to-
tal RNA were mixed with 2 
 
 
 
l oligo dT primers (16 mer, 0.5
mg/ml) and ddH
 
2
 
O to equalize volumes of all samples at 8.5 
 
 
 
l.
The mix was heated at 65
 
 
 
C for 10 min, quenched on ice, spin
down briefly, and 11.5 
 
 
 
l of a Master Mix was added. The RT
Master Mix consisted of 4 
 
 
 
l 5
 
  
 
first stand buffer (GIBCO
BRL), 4 
 
 
 
l 2.5 mM dNTPs, 2 
 
 
 
l 0.1 M DTT, 0.5 
 
 
 
l RNase in-
hibitor (40 U/
 
 
 
l; GIBCO BRL), and 1 
 
 
 
l Superscript II (200
 
 
 
l/
 
 
 
l; GIBCO BRL). The action was incubated at 37
 
 
 
C for 90
min, and then 95
 
 
 
C for 10 min, followed by 4
 
 
 
C soak. To each
sample (in 20 
 
 
 
l total volume) 80 
 
 
 
l ddH
 
2
 
O were added. 3 
 
 
 
l
were used for each PCR reaction of 25 
 
 
 
l in volume. The fol-
lowing primers were used for PCR amplification: human IL-12
p40 sense primer: CCAAGAACTTGCAGCTGAAG; antisense
primer: TGGGTCTATTCCGTTGTGTC; human IL-12 p35
sense primer: GATGAGCTGATGCAGGCC; antisense primer;
AGTCCTCCACCTCGTTGTCCGTGA; human IRF-1 sense
primer: CAAATCCCGGGGCTCATCTGG; antisense primer:
CTGGCTCCTTTTCCCCTGCTTTGT; human HPRT sense
primer: CCTGCTGGATTACATCAAAGCACTG; antisense
primer: TCCAACACTTCGTGGGGTCCT.
 
Chromatin Immunoprecipitation (ChIP) Assay.
 
The ChIP pro-
cedure was performed using an assay kit according to the manu-
facturer’s instructions (Upstate Biotechnology). In brief, 10
 
7 
 
gly-
collate-elicited peritoneal macrophages from C57BL/6 mice or
human peripheral blood monocytes were stimulated with 10 ng/
ml IFN-
 
  
 
priming and 1 
 
 
 
g/ml LPS or alone, and cross-linked by
1% formaldehyde for 10 min at 37
 
 
 
C. Nuclei were prepared and
subjected to sonication to obtain DNA fragments ranging from
200–1,000 bp. Chromatin fractions were precleared with protein
A agarose beads followed by immunoprecipitation overnight at
4
 
 
 
C with 3 
 
 
 
g anti–IRF-1 antibody and control antibody. Cross-
linking was reversed for 4 h at 65
 
 
 
C and was followed by protein-
ase K digestion. DNA was purified and subjected to PCR. The
input DNA were diluted 200 times before PCR. The input and
precipitated DNA were PCR amplified by primers encompassing
the IRF-1 site in the mouse IL-12 p35 promoter (5
 
  
 
primer:
TTGCTTTCGCTCTGAGTGTG and 3
 
  
 
primer: GCTGAC-
CTTGGGAGACACAT) and human IL-12 p35 promoter
(5
 
  
 
primer: GCGAACATTTCGCTTTCATT and 3
 
  
 
primer:
ACTTTCCCGGGACTCTGGT) in a buffer containing 2 mM
MgCl
 
2
 
. The samples were amplified for 34 cycles by PCR and an-
alyzed by electrophoresis on a 1.2% agarose gel.
 
Adenoviral Vectors and Their Propagation.
 
We integrated pTRE
into pAdeno-X express system (CLONTECH Laboratories, Inc.).
First, we amplified the mouse IRF-1 cDNA (mIRF-1) by RT-
PCR and subcloned it into the T/A cloning vector PCR2.1 (In-
vitrogen), and then transferred the mIRF-1 fragment (NotI and
KpnI) into pShuttle vector (NotI and KpnI). Finally, the mIRF-1
expression cassette was ligated with the pAdeno-X backbone by
I-CeuI and PI-sceI digestion. At the same time we constructed the
LacZ expression vector as a control by transferring the LacZ ex-
pression cassette into pAdeno-X using the same construction strat-
egy as described for the mIRF-1 vector. Viruses were propagated
in the HEK293 cell line (human embryonic kidney) and purified
by ultracentrifugation through two cesium chloride gradients. Ti-
ters of viral stocks were determined by plaque assay in HEK293
cells after exposure to virus for 1 h in serum-free DMEM and by
OD
 
260 
 
reading. Approximately 25 optical viral particles were
equivalent to 1 plaque-forming unit. Freshly isolated human
monocytes were cultured in 100 ng/ml human M-CSF for 6 d.
The resulting macrophages were exposed to recombinant virus for
4–8 h in serum-free RPMI 1640 medium followed by an equal
volume of RPMI 1640 supplemented with 10% fetal calf serum
for an additional 24 h. The transfection medium was replaced with
fresh RPMI 1640 medium with 10% FCS. 24 h later the transfec-
tion efficiency was monitored by 
 
 
 
-galactosidase staining (24) un-
der reverse-phase fluorescence microscope.
 
Statistical Analysis.
 
Student’s 
 
t
 
 test was performed wherever
applicable. Standard deviation of the mean is shown unless other-
wise indicated.
 
Results
 
Differential Impact of IRF-1 Deficiency on IL-12 p40 and
p70 Production. To determine the role of IRF-1 in the
regulation of IL-12 production we obtained inflammatory
peritoneal macrophages from IRF-1 /  mice and control
wild-type animals, and then stimulated them in vitro with
LPS or primed them with IFN-  followed by LPS stimula-
tion. IL-12 p40 and p70 production over a period of 24 h
was measured by specific ELISA. Because of the lack of a
p35-specific ELISA due to the fact that it is secreted only as
a heterodimer, measurement of p70 production is a gener-
ally accepted indicator of IL-12 p35 production due to the
stoichiometric nature of the p40-p35 dimerization. As
shown in Fig. 1, IL-12 p40 production stimulated by LPS
alone (Fig. 1 A) or IFN-  plus LPS (Fig. 1 B) was only
marginally lower in IRF-1 /  macrophages than in control
cells (no statistical significance). On the other hand, IL-12
p70 production induced by LPS (Fig. 1 C) or IFN-  plus
LPS (Fig. 1 D) was strongly decreased in IRF-1 /  cells.
Because IL-12 p70 consists p40 and p35 subunits in a 1:1
molar ratio, these data likely suggest that IRF-1 differen-
tially regulates IL-12 p40 and p35 gene expression. This
differential impact of IRF-1 deficiency on IL-12 p40 and
p70 production is not restricted to inflammatory macro-
phages as resident and bone marrow–derived macrophages
also exhibited very similar patterns (unpublished data).
To resolve the differences between our observation and
that of Taki et al. (10), which showed a defect of IL-12 p40
production in IRF-1 /  macrophages stimulated by IFN- 
and LPS, we compared the timing of IFN-  addition to the
cell culture, which is the main difference in the technical
protocol of the two studies. When IFN-  was added simul-
taneously with LPS, IL-12 p40 production was substantially
reduced in IRF-1 /  cells (Fig. 1 E) whereas p40 synthesisT
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was not impacted when IFN-  was used as a priming agent
(Fig. 1, A and B). IL-12 p70 production, however, was re-
duced in IRF-1 /  cells regardless of the timing of IFN- 
addition (Fig. 1, C, D, and F). This indicates that the
length of the exposure of macrophages to IFN-  before
seeing LPS determines their ability to produce IL-12 p40
whereas it is not able to rescue IL-12 p35 expression in the
absence of IRF-1.
Selective Impairment of IL-12 p35 mRNA Expression by
IRF-1 Deficiency. To determine the level of the differen-
tial effects of IRF-1 deficiency on IL-12 p40 and p35 gene
expression we examined their steady-state mRNA expres-
sion by RPA. Fig. 2 A shows that the level of IL-12 p40
mRNA induced by LPS alone or IFN-  plus LPS was
comparable between wild-type and IRF-1 /  peritoneal
macrophages. So were most of the other monokines pro-
duced under these conditions. However, the IL-12 p35
mRNA expression was severely impaired in IRF-1 /  cells
in LPS or IFN- /LPS–stimulated cells. These results sug-
gest that IRF-1 is preferentially involved in the transcrip-
tional regulation of the IL-12 p35 gene. In human periph-
eral blood monocytes, the IFN-  priming effect is highly
pronounced for IL-12 p35 and p40 mRNA expression
(Fig. 2 B, compare lanes 3 and 4), and the p35 gene appears
to be even more dependent on IFN-  priming than the
p40 gene. Moreover, in these cells, the mRNA expression
Figure 1. Differential impact of IRF-l deficiency on IL-12 p40 and p70 production. IL-12
p40 (A, B, and E) and p70 (C, D, and F) were measured by ELISA from cell-free supernatants
of thioglycollate-elicited inflammatory mouse peritoneal macrophage cultures (0.5   106
cells in 1 ml) stimulated with LPS (A and C) or primed with IFN-  for 16 h followed by
LPS (B and D) or LPS with IFN-  at same time (E and F) for the indicated times in hours.
 , wild-type macrophages; *, IRF-1–deficient cells. Results shown are mean plus SD of
four independent experiments.
Figure 2. Selective impairment of IL-12 mRNA
synthesis in IRF-1 /  macrophages. (A and B) RPA.
Total RNA was isolated from peritoneal macrophages
(A) or human peripheral blood monocytes (B) and sub-
jected to RPA. 10  g RNA were used for the analyses.
The intensities of mIL-12 p35 and p40 mRNA bands
in the top of A were quantified using the ImageQuant
software and normalized to the internal loading controls
L32 and GAPDH (A, bottom). Data are representative
of four separate experiments with very similar results.
(C) The IRF-1 mRNA expression was examined by
RT-PCR under the same conditions together with the
determination of mRNA expression of the housekeeping
gene HPRT. (D) IL-12 p35 protein expression was
analyzed by Western blot under reducing conditions
using an anti–IL-12 p35 antibody with whole cell lysates
(150  g per lane) isolated from human blood–derived
monocytes stimulated with LPS for 20 h with or without
IFN-  priming. The control used was reduced recom-
binant human IL-12 in two amounts: 200 and 510 pg.
Note that the IFN- /LPS–induced band in lane 4 ran
slightly slower than the control (rIL-12), possibly because
of the cell lysate overloading effect. Other bands that reacted with the antibody in lanes 1–4 are of undetermined nature. (E) The ratio of mIL-12 p40
versus p35 mRNA was derived from seven independent RPAs after normalization against the internal controls L32 and GAPDH. (F) The ratio of mIL-12
p40 to p70 proteins was derived from four separate experiments.T
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of IRF-1 is highly consistent with that of the IL-12 p35 as
shown in Fig. 2 C in that IFN-  and LPS synergistically in-
duced IRF-1 transcript synthesis (Fig. 2 C).
It has not been established if p35 production is directly
related to p35 mRNA levels. To demonstrate the relation-
ship between IL-12 p35 mRNA expression and its protein
synthesis, we analyzed the level of IL-12 p35 protein in
whole cell lysates derived from human monocytes stimu-
lated with IFN- , LPS, or both. As shown in Fig. 2 D, the
protein expression of IL-12 p35, detected by an anti-p35
antibody, was most induced by IFN-  and LPS together.
The level of this induction was comparable to that seen in
the IL-12 p35 mRNA level, indicating that there is no ma-
jor regulatory step between the level of p35 mRNA and its
translation. To test the assumption whether the discrepancy
between p40 and p70 released into the culture supernatant
is due to regulation of p35 production, we quantified the
ratio of IL-12 p40 versus p35 mRNA levels from seven in-
dependent RPAs in wild-type murine peritoneal macro-
phages stimulated with LPS or IFN-  plus LPS (Fig. 2 E).
The p40/p35 mRNA ratio was 3.4 in LPS-stimulated cells
and 11.2 in IFN- /LPS–stimulated cells. The p40/p70
protein ratio calculated from the four experiments in Fig.
1, A–D, was 11.2 in LPS-stimulated cells and 3.8 in IFN-
 /LPS–stimulated cells (Fig. 2 F). Taken together, these
results suggest that in macrophages activated by LPS, there
might be additional regulatory steps in the total output of
p70 other than transcription and translation of IL-12 p35,
such as the assembly of p40 and p35 to form p70 and its se-
cretion. In IFN- – and LPS-stimulated cells the p40 and
p35 proteins might be more efficiently assembled into p70
or secreted.
Regulatory Regions of the IL-12 p35 Promoter in IFN- /
LPS Response. To further explore the molecular mecha-
nism whereby IFN-  and LPS regulate IL-12 p35 tran-
scription through IRF-1, we analyzed the human IL-12
p35 promoter with respect to the important regions that
mediate transcriptional response to IFN- /LPS stimulation
by sequentially deleting the full-length promoter, a 1,143-
bp genomic fragment (8), from the 5  end. The transcrip-
tional start site of the human IL-12 p35 gene in macro-
phages has been mapped (25). We used a well-established
transient transfection cell model in the murine myeloid cell
line RAW264.7 using the firefly luciferase reporter gene
(8). The full-length IL-12 p35 promoter ( 61 to  1,082,
C1 construct) was highly responsive to stimulation by the
combination of IFN-  priming and LPS treatment whereas
LPS alone had little effect in the activation of p35 transcrip-
tion (Fig. 3 A). Sequential deletion of the full-length pro-
moter down to  392 (C2 and C3 constructs) had no visi-
ble impact on the inducibility of the p35 promoter by IFN- 
and LPS. A further deletion of 152 bp (to  240, C4 con-
struct) resulted in a complete loss in the response, indicat-
ing the presence of a critical cis element(s) in this region in-
volved in response to IFN-  and LPS. By this approach,
we identified the C3 construct as a minimal promoter
( 61 to  392) that retained full IFN- /LPS response, and
it was used for most of the subsequent experiments. In this
cell line, IFN- , not LPS, greatly induced nuclear IRF-1
protein expression (Fig. 3 B). Again, this illustrates that
IRF-1 is necessary but not sufficient to activate IL-12 p35
transcription. Additional LPS-induced factors, such as NF-
 B (12), have also been shown to be required to stimulate
the transcriptional response.
Role of LPS and NF- B in the Regulation of IL-12 p35
Transcription. The role of LPS in the induction of IL-12
p35 transcription has been addressed in a previous study by
Grumont et al. (12). This study demonstrated that the NF-
 B signaling pathway is necessary for the induction of IL-
12 in response to microbial stimuli. In particular, expression
of IL-12 p35 induced by Staphylococcus aureus, DNA, or LPS
is c-Rel dependent and regulated directly by c-Rel com-
plexes binding to the IL-12 p35 promoter (12). We over-
expressed NF- B p50, p65, and c-Rel by cotransfection
Figure 3. Critical regions of IL-12 p35 promoter in
IFN- /LPS response. (A) Various truncation constructs of
the human IL-12 p35 promoter luciferase reporter were
transiently transfected into RA W264.7 cells by electropora-
tion. Cells were stimulated with LPS alone (7 h), or IFN- 
(16 h) followed by LPS. Luciferase activity from each
construct was measured from cell lysates. Results shown
are mean plus SE of three to four independent experi-
ments. The promoter coordinates all refer to the first,
monocyte-specific transcription initiation site (TIS-1) located
at  1 (reference 25). The second, B cell–specific transcription
initiation site (TIS-2) located at  164 (reference 25) is also
indicated. (B) The endogenous IRF-1 protein expression
in RAW264.7 cells was analyzed by Western blot using an
affinity-purified polyclonal anti–IRF-1 antibody under the
same cellular stimulations.T
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with the IL-12 p35 promoter reporter in RAW264.7 cells
stimulated with LPS or IFN-  plus LPS (Fig. 4 A). Expres-
sion of p50 inhibited the p35 promoter activity stimulated
by LPS or IFN-  plus LPS whereas c-Rel strongly stimu-
lated the p35 transcription. NF- B p65 enhanced the p35
promoter activity in LPS-stimulated but not in IFN-  plus
LPS-stimulated cells. The essential role of the NF- B path-
way in the transcriptional activation of the IL-12 p35 gene
in this system was also confirmed by using a dominant pos-
itive mutant of I B , in which the two important serine
phosphorylation sites have been deleted such that the mu-
tant becomes resistant to phosphorylation-triggered degra-
dation, thus remaining constantly active in the cell. Block-
ing NF- B activation using this I B  mutant resulted in
strong inhibition of the IL-12 p35 promoter activity in-
duced by LPS, or IFN-  plus LPS, and of the p35 promoter
activity enhanced by p65 and c-Rel (Fig. 4 A).
Given the importance of LPS-induced NF- B c-Rel in
the transcriptional regulation of IL-12 p35, it was intrigu-
ing to ask this question: What is the role of TNF-  in the
regulation of IL-12 p35 gene expression since it can also
activate the NF- B pathway? We first analyzed IL-12 p35
mRNA expression in freshly isolated mouse peritoneal
macrophages after stimulation with LPS, TNF- , IFN- 
plus LPS, or IFN-  plus TNF- . As shown in Fig. 4 B,
TNF- , when used alone or in combination with IFN- ,
only slightly induced IL-12 p35 mRNA. In the same cells,
TNF- , unlike LPS, failed to induce significant nuclear ex-
pression of c-Rel although it strongly activated NF- B p65
(Fig. 4 C). Thus, TNF-  cannot substitute for LPS for the
induction of IL-12 p35 gene expression potentially because
TNF-  lacks the ability to activate the critical c-Rel in
these macrophages. This is consistent with the finding in
our previous study in human macrophages (26).
Differential Regulation of Transcription of IL-12 p40 and p35
by IRF-1. To study the role of IRF-1 in transcriptional
activation of the p35 promoter we took advantage of the
observation that in RAW264.7 cells, IRF-1 expression is
solely induced by IFN-  but not by LPS treatment (Fig. 3
B). This allows measurement of the response of the IL-12
p35 promoter to exogenously introduce IRF-1 expression
by transient transfection in LPS-stimulated cells without
the concern of the presence of significant amounts of en-
dogenous IRF-1. It also provides a unique setting to assess
the synergism between IFN- –induced signals, which are
mimicked by the activities of IRF-1, and those mediated
by LPS.
The full-length IL-12 p35 promoter ( 61 to  1,082)
was transiently transfected into RAW264.7 cells together
with a vector constitutively expressing mouse IRF-1 or
IRF-2, the antagonistic repressor of IRF-1 (17), under the
  actin promoter, or the parental control vector. The trans-
fected cells were subsequently stimulated with LPS. Fig. 5
A shows that the p35 promoter was not activated in LPS-
stimulated cells by the control or IRF-2 expression vector
at various molar ratios of effector (IRF-1, IRF-2, or con-
trol vector) to reporter (p35 promoter luciferase construct).
Cotransfection with the IRF-1 effector plasmid induced a
dose-dependent activation of the IL-12 p35 promoter. In
contrast, cotransfection of the same amounts of IRF-1 with
the human IL-12 p40 promoter ( 3,300 to  108; refer-
ence 5) resulted in little transcriptional activation (Fig. 5 B).
Taken together, these results indicate that IRF-1 has a dif-
ferential ability to regulate IL-12 p35 and p40 transcription
in synergy with LPS.
Localization of IRF-1 Response Element in IL-12 p35 Pro-
moter. To further localize the putative IRF-1 response el-
ement in the IL-12 p35 promoter, a computer-assisted
Figure 4. Role of LPS and NF- B in the regulation
of IL-12 p35 transcription. (A) c-Rel can activate IL-12
p35 transcription. RAW264.7 cells were transiently
transfected with the full-length IL-12 p35 promoter, as
described in Fig. 3, together with an expression vector
for NF- B p50, p65, or c-Rel at a 1:1 molar ratio (effec-
tor to reporter) with or without the I B  mutant, also
at a 1:1 molar ratio. Data are representative of four
independent experiments (mean plus SE), expressed as
relative induction over the baseline (medium) of each
cotransfection, which was set as 1 (indicated by a dotted
line). (B) TNF-   cannot substitute for LPS. Mouse
peritoneal macrophages were treated with LPS, 10 ng/ml
mTNF-   for 4 h, or in combination with IFN- 
(priming). Total RNA was subjected to RT-PCR to
measure IL-12 p35 mRNA expression. HPRT mRNA
was also measured as a loading control. Data are repre-
sentative of two independent experiments. (C) TNF- 
activates poorly the nuclear translocation of c-Rel.
Nuclear extracts were obtained from mouse peritoneal
macrophages used in the experiment described in B,
and analyzed by Western blot using anti–c-Rel and
anti-p65 polyclonal antibodies (20  g nuclear extract
per lane).T
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scanning was performed and a sequence, GCTTTC-
ATTTT located at  235 to  243 that matched with the
consensus IRF-1 sequence in reverse, AAAATGAAAGC,
was identified (Fig. 6 A).
To determine if this region was critical for the IRF-1 re-
sponse we compared the ability of the C3 and C4 con-
structs (Fig. 3 B) to be activated by IRF-1 in LPS-stimu-
lated cells (Fig. 6 B). The C4 construct truncates in the
middle of the putative IRF-E site at  240. The minimal
p35 promoter construct C3 (Fig. 3 B) appeared to harbor
the potential IRF-1 response element because a further de-
letion of 152 bp from the 5  end resulted in the loss of re-
sponse to IRF-1. Thus, the IFN- /LPS response element
and the IRF-1 element were both placed in the same re-
gion of the p35 promoter (between  240 and  392).
To further establish if the putative IRF-E was important
for the response of the p35 promoter to IFN-  and LPS,
point mutations (4 bp) were introduced into this site in the
context of the minimal promoter (C3 construct,  61 to
 392). The wild-type and mutant promoter constructs
were transiently transfected into RAW264.7 cells followed
by stimulation with LPS or IFN-  or a combination of the
two (Fig. 6 C). The response of the mutant promoter to
IFN-  alone or IFN-  plus LPS was severely diminished
compared with the response of the wild-type promoter, in-
dicating that the putative IRF-1 site is indeed critical for
the IFN-  response of the p35 promoter.
To find out if this site was required for IRF-1 response,
the wild-type and mutant constructs were cotransfected
with the IRF-1 expression vector into RAW264.7 cells at
various molar ratios of effector to reporter followed by LPS
activation. The mutant promoter construct completely lost
its ability to respond to transcriptional activation by IRF-1
(Fig. 6 D), suggesting that this site indeed mediates the
IRF-1 response.
A recent study by Goriely et al. (27) showed that the two
Sp1 elements located at  352/ 349 and  297/ 294, re-
spectively, were essential for the response of the IL-12 p35
promoter to LPS and IFN- –induced transcription. We
confirmed this finding by mutating the two sites in the
context of the  392/ 61 construct, both of which re-
sulted in significant reduction of the p35 promoter activa-
tion by LPS and IFN-  (Fig. 6 E). Furthermore, mutations
at these sites also affected negatively their response to tran-
scriptional activation by IRF-1 (Fig. 6 F). These results
suggest that there might be interactions between the SP1
elements and the IRF-E site through transcription factors
that bind to them, and that these interactions produce a
synergistic effect on the p35 promoter.
Specific Binding of IRF-1 to IRF-E In Vitro and In Vivo
upon Cellular Activation. To determine if IRF-1 could
physically interact with the IRF-E in the p35 promoter,
DNA affinity binding assays were performed. Fig. 7 A
demonstrates that upon IFN-  activation, a portion of the
endogenous IRF-1 specifically bound to this site (Fig. 7 A,
top, lanes 2 and 4), but not to the mutant site (Fig. 7 A,
top, lanes 6 and 8). The unbound fractions (Fig. 7 A, two
bottom panels) contained similar amounts of IRF-1 and
PU.1 regardless of the DNA ligand (wild-type or IRF-1
mutant) they interacted with. These results strongly indi-
cate that the IRF-E located at  235 to  243 is essential
for IFN- /IRF-1 response of the IL-12 p35 promoter and
it specifically interacts with the endogenously produced
IRF-1 upon IFN-  stimulation. Interestingly, unlike the
regulation of IL-12 p40 gene transcription (22), we did not
find ICSBP in the IRF-1 complex (unpublished data).
To determine if the endogenous IRF-1 interacts with
this region of the promoter of the chromosomal IL-12 p35
gene, we performed ChIP analysis, which allows for the
examination of specific protein–DNA interactions in the
context of living cells (23). Fig. 7 B depicts a pair-wise
alignment of the human and mouse IL-12 p35 promoters
in the region harboring the IRF-E and the primers used to
analyze the DNA–protein interaction by genomic PCR.
As shown in Fig. 7 C, specific interaction between the en-
dogenous IRF-1 and IL-12 p35 promoter was detected in
LPS- or IFN- –stimulated mouse peritoneal macrophages
(Fig. 7 C, lanes 10–12) but not in unstimulated cells (Fig.
7 C, lane 9). In the presence of a control antibody (rabbit
IgG), there was no specific amplification of the chromo-
Figure 5. Differential regulation of transcription of IL-12 p35 and p40
by IRF-l. (A) The full-length IL-12 p35 promoter ( 61/ 1082) reporter
construct was cotransfected with an IRF-1, IRF-2, or the parental ex-
pression vector into RAW264.7 cells at various effector/reporter molar
ratios as indicated. After LPS stimulation (7 h), luciferase activity was
measured and expressed as fold change over that of the unstimulated cells
within each cotransfection. Results are mean plus SE from four independent
experiments. (B) The full-length IL-12 p35 and p40 promoter reporter
constructs were cotransfected, respectively, with IRF-1 expression vector
into RAW264.7 cells at various effector/reporter molar ratios. After LPS
stimulation, luciferase activity was measured and expressed as fold change
induced by IRF-1 over that by the control vector within each cotransfection.
Results are mean plus SE from three independent experiments.T
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somal DNA derived from the IL-12 p35 promoter (Fig. 7
C, lanes 5–8), whereas amplification of the input DNA
was efficient and constant in all four samples (Fig. 7 C,
lanes 1–4). Note that in mouse peritoneal macrophages,
unlike RAW264.7 cells, IFN-   as well as LPS induce
IRF-1 expression (Fig. 7 E). Likewise, in human periph-
eral blood–derived monocytes, specific IRF-1 binding to
this region of the endogenous IL-12 p35 promoter was
also detected albeit primarily in IFN-  and LPS-costimu-
lated cells (Fig. 7 D, lane 12). This is consistent with the
observation that unlike in mouse peritoneal macrophages
(Fig. 7 E) or RAW264.7 cells (Fig. 3 B), IRF-1 nuclear
expression in human monocytes was principally induced
by a combination of IFN-  and LPS, rather than by either
stimulus alone (Fig. 7 F, lane 4). Thus, the ChIP patterns
match perfectly with those of the IRF-1 expression in
both mouse and human macrophages. These results dem-
onstrate a specific and physiological association of activa-
tion-induced IRF-1 with the IL-12 p35 promoter at the
IRF-E site.
IRF-1 Expression Enhances IL-12 p35 Expression and p70
Production. Our working model at this point was that
IRF-1 serves as a critical transcription factor for high levels
of IL-12 production in macrophages by selectively activat-
ing p35 in the presence of a microbial signal. We have
demonstrated this by the reduced IL-12 p35 mRNA ex-
pression and p70 protein production in IRF-1 /  macro-
phages, and by the ability of exogenous IRF-1 to activate
IL-12 p35 promoter reporter activity in transient transfec-
tions in a cell line. To further demonstrate the effect of
IRF-1 on the endogenous IL-12 p35 gene transcription in
primary macrophages, we constructed adenovirus vectors
expressing the murine IRF-1 or the  -galactosidase gene
(LacZ), transduced human monocyte–derived macro-
phages with these viral expression vectors at the multiplic-
ity of infection (MOI) of 160 and 320 for 48 h, and mea-
sured IL-12 p70 production after stimulation with LPS
(Fig. 8 A). The LacZ-expressing virus did not stimulate IL-
12 production in the absence or presence of LPS. Adeno-
virus-mediated IRF-1 expression induced IL-12 p70 pro-
Figure 6. Localization of the IRF-1 response element.
(A) The sequence of the minimal IL-12 p35 promoter
( 61/ 392). Putative cis elements were predicted using
MatInspector 3.3. The two transcriptional initiation
sites, TIS-1 and TIS-2, are indicated. (B) Three of the
IL-12 p35 promoter reporter constructs were cotrans-
fected with the IRF-1 expression vector at the molar
ratio of 0.12 (effector/reporter), stimulated with LPS,
and luciferase activity was measured as above. (C) Effects
of mutations in the IRF-E site on the IFN-  and LPS
response of the IL-12 p35 promoter. Site-specific
mutations (4 bp) were introduced into the IRF-E site
at  235 to  245 in the context of the minimal promoter
( 61 to  392) as indicated below the graph. The
wild-type and mutant promoter constructs were trans-
fected into RA W264.7 cells, stimulated with IFN- ,
LPS, or a combination of the two. Luciferase activity
was measured from cell lysates. The data were normalized
against the values obtained with the mutant construct,
which was set as 1. (D) Effects of mutations in the
IRF-E site on the IRF-l response. The wild-type and
IRF-E mutant p35 promoter constructs were transiently
cotransfected into RAW264.7 cells with the IRF-1
expression vector at various effector to reporter molar
ratios as indicated. Luciferase activity was measured
after LPS stimulation and expressed as fold of stimulation
over that of unstimulated cells. (E) The C3 IL-12 p35
promoter construct ( 61 to  392) was mutated at the
two Sp1 sites as indicated (the underlined nucleotides
are substitutions). The mutant constructs were transfected
and luciferase activity was measured after appropriate
stimulation of the cells. All data are normalized to the
activity of the wild-type, unstimulated (medium) p35
promoter, which is set as 1. Results shown are combined
from three separate experiments with SEM. (F) The
wild-type and Sp1 mutant constructs were cotransfected
with the IRF-1 expression vector at a molar ratio of 0.12
(effector/reporter) and luciferase activity was measured
after LPS stimulation. Data are normalized against non-
LPS–stimulated wild-type promoter activity, which is
set as 1.T
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Figure 7. Specific binding of IRF-1 to the IRF-1 response element. (A) A 21-bp oligonucleotide harboring the IRF-E site of the human IL-12 p35
promoter ( 229 to  249) and its mutational derivative containing 4-bp changes within the IRF-E site were used as DNA ligand in affinity binding assays
with nuclear extracts isolated from RAW264.7 cells stimulated as indicated. The bound and unbound (washes) fractions were analyzed by Western blot
using an anti–IRF-l antibody. The unbound fractions were also stripped and reprobed with an anti-PU.l antibody to have an independent parameter.
The sequences of the two oligos are described with the IRF-E in bold and the mutations are underlined. The positive control used was a nuclear extract
isolated from IFN- –stimulated RAW264.7 cells. The results shown are representative of four independent tries with very similar outcomes. (B) Sequence
alignment of human and mouse IL-12 p35 promoter regions. The human (top line) and mouse (bottom line) promoters that contain the IRF-E site are
aligned with respect to the IRF-E site (boxed). The promoter coordinates with respect to the transcription start sites are shown. The lined arrows indicate the
PCR primers used in ChIP analysis shown in C and D. (C and D) IRF-1 binding in vivo. ChIP analysis was performed according to the procedure
described in Materials and Methods in mouse peritoneal macrophages (C) and in human blood–derived monocytes (D). The amplified mouse and human
genomic fragments derived from the endogenous IL-12 p35 promoter encompassing the IRF-E are indicated. Gel size markers are labeled in basepairs.
The control antibody was an isotype-matched rabbit IgG. (E and F) Western blot analysis of IRF-1 nuclear expression in mouse peritoneal macrophages
(E) and human monocytes (F) after appropriate stimulation as indicated.T
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duction at an MOI of 160 or 320 in the absence of LPS,
and further enhanced p70 in the presence of LPS. Consis-
tent with the induction of IL-12 production by the intro-
duction of IRF-1–expressing adenovirus, IRF-1 protein
expression in the nucleus was strongly enhanced in Ad/
IRF-1– but not Ad/Laz-transduced macrophages (Fig. 8
B). Moreover, IL-12 p35 mRNA but not p40 was also
slightly induced by IRF-1 alone, and greatly enhanced in
the presence of LPS (Fig. 8 C). The pattern of p35 mRNA
expression affected by IRF-1 matches quite well with that
of p70 production, further demonstrating the selective role
of IRF-1 in IL-12 p35 regulation.
Discussion
IRF-1 and IL-12 are both crucial players in immune de-
fense against infectious and malignant diseases. The regula-
tory relationship between them is a subject of great interest.
A previous study by Grumont et al. (12) investigated the
regulation of the IL-12 p35 gene in response to microbial
stimulation using c-Rel knockout mice. This study shows
that NF- B c-Rel is essential for the transcriptional re-
sponse of the p35 gene but not the p40 gene to microbial
stimuli such as S. aureus, CpG DNA, or LPS. We confirm
that the NF- B signaling pathway is indeed essential for
the transcriptional activation of IL-12 p35 by LPS (Fig. 4
A). TNF- , which is able to activate the NF- B pathway,
is nonetheless unable to activate c-Rel particularly (Fig. 4
C), thus explaining to some extent its inability to substitute
for LPS in the transcriptional regulation of IL-12 p35 (Fig.
4 B). It is noted that in our transient transfection system,
NF- B p65, when overexpressed, is also able to activate
LPS-stimulated p35 promoter activity (Fig. 4 A). This ob-
servation is inconsistent with the ability of TNF-  to acti-
vate NF- B p65 (Fig. 4 C). The explanation for this appar-
ent contradiction may lie in the fact that in LPS-stimulated
RAW264.7 cells, the endogenous c-Rel is activated, thus
making it possible for the p65-mediated induction of the
IL-12 p35 transcription. This explanation does not apply to
the effect of NF- B p50 because its overexpression could
lead to formation of p50/p50 homerdimers, which are
transcriptionally inhibitory as we have shown previously on
the IL-12 p40 transcription (28).
In this study, we demonstrate the molecular mechanisms
whereby IRF-1, primarily induced by IFN- , selectively
regulates the transcriptional activation of the IL-12 p35
gene (Fig. 5 B). IRF-1 does so by directly binding to the
p35 promoter at the IRF-E site (Fig. 7) and activates the
promoter possibly in synergy with other essential factors
such as Sp1 (Fig. 6, E and F; reference 27) and NF- B in-
duced by LPS (12). These findings clearly provide the
mechanistic basis of IFN-  priming for potent IL-12 pro-
duction in immune responses and illustrate the complexity
of coordination and discordance in the regulation of multi-
subunit, heterologous molecules such as IL-12.
The lack of a strong deficiency in IL-12 p40 mRNA
expression in IRF-1 /  macrophages shown in this study
is in apparent disagreement with the results of two previ-
ous studies (10, 29). The possible reason(s) for this dis-
crepancy was investigated in our study, which indicates
that prolonged exposure of macrophages to IFN-  before
LPS stimulation is able to rescue the deficiency in IL-12
p40 production in IRF-1 /  cells (Fig. 1, A and B) via an
alternative, uncharacterized mechanism. This unknown
alternative pathway is unlikely to play a role in IL-12 p35
and p70 production because they are not rescued by the
IFN-  pretreatment. The rescue effect of IFN-  pretreat-
ment on IL-12 p40 expression in IRF-1 /  macrophages
was also observed in a previous study by Salkowski et al.
(11). The differential impact of the length of IFN-  pre-
Figure 8. IRF-1 expression enhances IL-12 p35 ex-
pression and p70 production. (A) Human monocyte–
derived macrophages were transduced with Ad/IRF-l
or Ad/LacZ at an MOI of 160 or 320 plaque-forming
units per cell followed by stimulation with LPS (24 h).
IL-12 p70 production was measured from the culture
supernatant by ELISA. The transduction rate assessed
by LacZ staining indicated that  40% at 160 MOI and
70% at 320 MOI. Data shown are representative of two
independent experiments with similar results. (B) IRF-1
protein expression in adenovirus-transduced macro-
phages. Resting human macrophages were transduced
with an adenovirus expression vector containing
mIRF-l cDNA (Ad/IRF-l) or LacZ cDNA (Ad/LacZ)
for 24 h. Nuclear extracts were isolated and analyzed
by Western blot using an anti–IRF-l antibody (top).
33  g cytoplasmic and nuclear extracts were used in
each lane. The membrane was stripped and reblotted
with an anti-PU.1 antibody to ensure equal protein
loading (bottom). (C) IL-12 p35 and p40 mRNA ex-
pression in the above experiment in A was measured by
conventional RT-PCR under nonsaturating conditions.
HPRT mRNA expression from the same samples was
measured as a loading control.T
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treatment on p40 but not on p70 production supports the
notion that IRF-1 contributes to the transcriptional regu-
lation of IL-12 p40 and p35 genes through different
mechanisms.
The discrepancy in the degree of IFN-  dependency of
the IL-12 p35 gene for its mRNA expression between hu-
man monocytes and mouse macrophages has been noted
by us for some time. The lesser IFN-  dependency of
mouse peritoneal macrophages for p35 mRNA expression
is not due to preactivation of these cells by thioglycollate
as we observed the same patterns in resident macrophages
(unpublished data). It is not due to the differences between
human monocytes and macrophages generated from
freshly isolated monocytes in M-CSF because the latter
cells are just as dependent on IFN-  as the former for IL-
12 p35 mRNA expression (30). It is correlated, however,
with the ability of the cells to express IRF-1 in response to
IFN-  or LPS. As we show in Fig. 7 E, either LPS or
IFN-  is able to induce nuclear IRF-1 expression whereas
in human monocytes abundant IRF-1 is induced only by a
combination of LPS and IFN-  (Fig. 7 F). These patterns
of IRF-1 expression correlate with the degree to which
the cells are dependent on IFN-  for the activation of IL-
12 p35 transcription.
We provide conclusive evidence that the total amount of
IL-12 p35 protein synthesized in IFN-  and LPS-stimulated
cells correlates with that of its mRNA (Fig. 2, B and D), in-
dicating that there is no major regulatory step involved be-
tween mRNA and translation. However, the differences in
IL-12 p40/p35 mRNA and p40/p70 protein ratios indicate
that the previous general assumption that p35 mRNA levels
correspond to those of p70 synthesis is an oversimplifica-
tion. Posttranscriptional mechanisms may exist that regulate
the assembly of p35 into the heterodimeric complex with
p40 or the secretion of p70 (31, 32).
The results derived from our study may have significant
impact on the regulation of immune responses exerted by
IFN- . It could be speculated that during a microbial in-
fection, the infectious agent such as bacteria stimulates in-
nate immune cells such as macrophages to produce the ini-
tial, small amount of IL-12, which then activates NK cells
to produce IFN- . This IFN-  production would act as a
costimulatory factor for macrophages in the presence of
the microbial agent to induce much larger amounts of IL-
12 production via transcriptional activation of IL-12 p40
primarily by ICSBP (33), and p35 via IRF-1, both in-
duced by IFN- . This second wave, large amount of IL-
12 production can exert both local and systemic effects on
APCs and lymphocytes in the ensuing adaptive phase of
the immune response.
In summary, this study has established the molecular basis
and elucidated the operational details of the selective regula-
tion of IL-12 p35 gene transcription by IRF-1 in its control
of IL-12 production in response to pathogenic perturbation.
It provides a mechanistic explanation for the synergistic acti-
vation of IL-12 production and enhanced immune activation
by the perpetual stimulation delivered by cellular factors such
as IFN-  and microbial agents such as LPS.
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